Spotfire and BioImagene announced that they have integrated their products to speed decision-making for their life science customers. BioImagene's SIMS (Scientific Image Management Systems) rich image data mining repository has been integrated with Spotfire DecisionSite visual, interactive analytics software, providing an end-to-end solution for research analysts in the life science market segment. The combined offering will be generally available to customers from May onwards. Read the press release.
EMC Corp. has introduced a midrange storage solution: the CLARiiON UltraScale architecture and CX3 series of networked storage systems. The new CLARiiON CX3 UltraScale series is designed to support customers' information lifecycle management strategies by enabling the consolidation of multiple tiers of information onto a single array while optimizing performance and total cost of ownership. The new CLARiiON UltraScale architecture offers full end-to-end 4 gigabit-per-second (Gb/s) Fibre Channel technology. Read the press release.
Illumina announced that it has installed a genotyping BeadLab in the Genetics Facility at the Shafallah Center for Children with Special Needs in Doha, Qatar. The BeadLab will anchor the first phase of the Shafallah Center's transformation into a world-class center of research excellence, integrating child-centered capabilities that range from genomics and disease discovery to existing strengths in clinical treatment, special education and related paramedical services. Read the press release.
Avidia, a privately-held biopharmaceutical company focused on discovering and developing a new class of human therapeutic proteins called avimers, today announced that it has raised $43.8 million in a Series C financing round. The company expects to use the proceeds to continue to advance the development of its lead products, which include an inhibitor of interleukin 6 for the treatment of inflammation and autoimmune disease, scheduled to enter clinical trials this year, and an inhibitor of IgE, on track to enter clinical trials next year. Read the press release.